|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Papakonstantinou E, Stamatopoulos A,
Athanasiadis DI, Kenanidis E, Potoupnis M, Haidich AB and Tsiridis
E: Limb-salvage surgery offers better five-year survival rate than
amputation in patients with limb osteosarcoma treated with
neoadjuvant chemotherapy. A systematic review and meta-analysis. J
Bone Oncol. 25:1003192020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meazza C and Scanagatta P: Metastatic
osteosarcoma: A challenging multidisciplinary treatment. Expert Rev
Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hattinger CM, Patrizio MP, Magagnoli F,
Luppi S and Serra M: An update on emerging drugs in osteosarcoma:
Towards tailored therapies? Expert Opin Emerg Drugs. 24:153–171.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leong PK and Ko KM: Schisandrin B: A
double-edged sword in nonalcoholic fatty liver disease. Oxid Med
Cell Longev. 2016:61716582016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nasser MI, Zhu S, Chen C, Zhao M, Huang H
and Zhu P: A comprehensive review on Schisandrin B and its
biological properties. Oxid Med Cell Longev. 2020:21727402020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang X, Wang S, Mu Y and Zheng Y:
Schisandrin B inhibits cell proliferation and induces apoptosis in
human cholangiocarcinoma cells. Oncol Rep. 36:1799–1806. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nasser MI, Han T, Adlat S, Tian Y and
Jiang N: Inhibitory effects of Schisandrin B on human prostate
cancer cells. Oncol Rep. 41:677–685. 2019.PubMed/NCBI
|
|
9
|
Dai X, Yin C, Guo G, Zhang Y, Zhao C, Qian
J, Wang O, Zhang X and Liang G: Schisandrin B exhibits potent
anticancer activity in triple negative breast cancer by inhibiting
STAT3. Toxicol Appl Pharmacol. 358:110–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang Y, Zhang Q, Bao J, Du C, Wang J,
Tong Q and Liu C: Schisandrin B suppresses glioma cell metastasis
mediated by inhibition of mTOR/MMP-9 signal pathway. Biomed
Pharmacother. 74:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lv XJ, Zhao LJ, Hao YQ, Su ZZ, Li JY, Du
YW and Zhang J: Schisandrin B inhibits the proliferation of human
lung adenocarcinoma A549 cells by inducing cycle arrest and
apoptosis. Int J Clin Exp Med. 8:6926–6936. 2015.PubMed/NCBI
|
|
12
|
Pautke C, Schieker M, Tischer T, Kolk A,
Neth P, Mutschler W and Milz S: Characterization of osteosarcoma
cell lines MG-63, Saos-2 and U-2 OS in comparison to human
osteoblasts. Anticancer Res. 24:3743–3748. 2004.PubMed/NCBI
|
|
13
|
Jiao Y, Guo Y, Fan Y, Wang R, Li X, Wu H,
Meng Z, Yang X, Cui Y, Liu H, et al: Triggering of apoptosis in
osteosarcoma 143B cell line by carbon quantum dots via the
mitochondrial apoptotic signal pathway. Biomed Res Int.
2020:28462972020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47(D1):D607–D613. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. Nat
Genet. 25:25–29. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
The Gene Ontology Consortium, . The gene
ontology resource: 20 years and still GOing strong. Nucleic Acids
Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanehisa M: Post-genome Informatics.
Oxford University Press; Oxford: 2000
|
|
19
|
R Core Team: R: A language and environment
for statistical computing. R Foundation for Statistical Computing;
Vienna, Austria: 2012
|
|
20
|
R Studio Team, . R Studio: Integrated
Development for R. R Studio, Inc.; Boston, MA: 2015
|
|
21
|
Stockhausen K: The Declaration of
Helsinki: Revising ethical research guidelines for the 21st
century. Med J Aust. 172:252–253. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rohani MG and Parks WC: Matrix remodeling
by MMPs during wound repair. Matrix Biol. 44–46. 113–121.
2015.PubMed/NCBI
|
|
24
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia P and Xu XY: PI3K/Akt/mTOR signaling
pathway in cancer stem cells: From basic research to clinical
application. Am J Cancer Res. 5:1602–1609. 2015.PubMed/NCBI
|
|
26
|
Jafari M, Ghadami E, Dadkhah T and
Akhavan-Niaki H: PI3k/AKT signaling pathway: Erythropoiesis and
beyond. J Cell Physiol. 234:2373–2385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21 Suppl 7:vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Armstrong J and Dass CR: Doxorubicin
action on mitochondria: Relevance to osteosarcoma therapy? Curr
Drug Targets. 19:432–438. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harrison DJ, Geller DS, Gill JD, Lewis VO
and Gorlick R: Current and future therapeutic approaches for
osteosarcoma. Expert Rev Anticancer Ther. 18:39–50. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hagleitner MM, Coenen MJ, Gelderblom H,
Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW,
Flucke U, van Leeuwen FN, et al: A first step toward personalized
medicine in osteosarcoma: Pharmacogenetics as predictive marker of
outcome after chemotherapy-based treatment. Clin Cancer Res.
21:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang
Z and Han J: The advantages of using traditional Chinese medicine
as an adjunctive therapy in the whole course of cancer treatment
instead of only terminal stage of cancer. Biosci Trends. 9:16–34.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Fang Z, Song C, Kang H, Guo Q,
Dong Y, Zhang Y, Peng R, Guan H and Li F: Schisandrin B inhibits
osteoclastogenesis and protects against ovariectomy-induced bone
loss. Front Pharmacol. 11:11752020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gruber M, Handle F and Culig Z: The stem
cell inhibitor salinomycin decreases colony formation potential and
tumor-initiating population in docetaxel-sensitive and
docetaxel-resistant prostate cancer cells. Prostate. 80:267–273.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kume K and Nishizuka SS: Colony lysate
arrays for proteomic profiling of drug-tolerant persisters of
cancer cell. Anal Chem. 89:8626–8631. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mailand N, Gibbs-Seymour I and
Bekker-Jensen S: Regulation of PCNA-protein interactions for genome
stability. Nat Rev Mol Cell Biol. 14:269–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang SC: PCNA: A silent housekeeper or a
potential therapeutic target? Trends Pharmacol Sci. 35:178–186.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cui J, Dean D, Hornicek FJ, Chen Z and
Duan Z: The role of extracelluar matrix in osteosarcoma progression
and metastasis. J Exp Clin Cancer Res. 39:1782020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McCabe EM and Rasmussen TP: lncRNA
involvement in cancer stem cell function and epithelial-mesenchymal
transitions. Semin Cancer Biol. 75:38–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Skrzypek K and Majka M: Interplay among
SNAIL transcription factor, MicroRNAs, long non-coding RNAs, and
circular RNAs in the regulation of tumor growth and metastasis.
Cancers (Basel). 12:2092020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The role of snail in EMT and tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mendonsa AM, Na TY and Gumbiner BM:
E-cadherin in contact inhibition and cancer. Oncogene.
37:4769–4780. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ramkumar N, Omelchenko T, Silva-Gagliardi
NF, McGlade CJ, Wijnholds J and Anderson KV: Crumbs2 promotes cell
ingression during the epithelial-to-mesenchymal transition at
gastrulation. Nat Cell Biol. 18:1281–1291. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Paolillo M and Schinelli S: Extracellular
matrix alterations in metastatic processes. Int J Mol Sci.
20:49472019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Torzilli PA, Bourne JW, Cigler T and
Vincent CT: A new paradigm for mechanobiological mechanisms in
tumor metastasis. Semin Cancer Biol. 22:385–395. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nørregaard KS, Jürgensen HJ, Gårdsvoll H,
Engelholm LH, Behrendt N and Søe K: Osteosarcoma and metastasis
associated bone degradation-A tale of osteoclast and malignant cell
cooperativity. Int J Mol Sci. 22:68652021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ogrodnik M, Salmonowicz H, Jurk D and
Passos JF: Expansion and cell-cycle arrest: Common denominators of
cellular senescence. Trends Biochem Sci. 44:996–1008. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Goel S, DeCristo MJ, McAllister SS and
Zhao JJ: CDK4/6 inhibition in cancer: Beyond cell cycle arrest.
Trends Cell Biol. 28:911–925. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pack LR, Daigh LH and Meyer T: Putting the
brakes on the cell cycle: Mechanisms of cellular growth arrest.
Curr Opin Cell Biol. 60:106–113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Montalto FI and De Amicis F: Cyclin D1 in
cancer: A molecular connection for cell cycle control, adhesion and
invasion in tumor and stroma. Cells. 9:E26482020. View Article : Google Scholar
|
|
52
|
Caruso JA, Duong MT, Carey JP, Hunt KK and
Keyomarsi K: Low-molecular-weight cyclin E in human cancer:
Cellular consequences and opportunities for targeted therapies.
Cancer Res. 78:5481–5491. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
D'Amelio M, Cavallucci V and Cecconi F:
Neuronal caspase-3 signaling: Not only cell death. Cell Death
Differ. 17:1104–1114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xu P, Cai X, Zhang W, Li Y, Qiu P, Lu D
and He X: Flavonoids of Rosa roxburghii Tratt exhibit
radioprotection and anti-apoptosis properties via the
Bcl-2[Ca(2+)]/Caspase-3/PARP-1 pathway. Apoptosis. 21:1125–43.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cai Y, Cai T and Chen Y: Wnt pathway in
osteosarcoma, from oncogenic to therapeutic. J Cell Biochem.
115:625–631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Danieau G, Morice S, Rédini F, Verrecchia
F and Royer BB: New insights about the Wnt/β-Catenin signaling
pathway in primary bone tumors and their microenvironment: A
promising target to develop therapeutic strategies? Int J Mol Sci.
20:37512019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi
X and Hoang BH: The Wnt signaling pathway: Implications for therapy
in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Revathidevi S and Munirajan AK: Akt in
cancer: Mediator and more. Semin Cancer Biol. 59:80–91. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang Q, Jiang W and Hou P: Emerging role
of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer
Biol. 59:112–124. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen Y, Li H, Zhang W, Qi W, Lu C, Huang
H, Yang Z, Liu B and Zhang L: Sesamin suppresses NSCLC cell
proliferation and induces apoptosis via Akt/p53 pathway. Toxicol
Appl Pharmacol. 387:1148482020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liang XX, Wang RY, Guo YZ, Cheng Z, Lv DY,
Luo MH, He A, Luo SX and Xia Y: Phosphorylation of Akt at Thr308
regulates p-eNOS Ser1177 during physiological conditions. FEBS Open
Bio. 11:1953–1964. 2021. View Article : Google Scholar : PubMed/NCBI
|
